'''Fluotracen''' ('''SKF-28,175''') is a [[tricyclic]] [[drug]] which possesses dual [[antidepressant]] and [[antipsychotic]] activity.<ref name="isbn0-12-040514-8">{{cite book | title = Annual Reports in Medicinal Chemistry: v. 14 | publisher = Academic Press Inc.,U.S | location = | year = 1979 | pages = | isbn = 0-12-040514-8 | oclc = | doi = | url = https://books.google.com/books?id=D4Cv8Ol4BV8C&lpg=PA15&as_brr=3&pg=PA15#v=onepage&q&f=false}}</ref><ref name="pmid410422">{{cite journal |vauthors=Fowler PJ, Zirkle CL, Macko E | title = Fluotracen: a tricyclic compound with the combined properties of antidepressants and antipsychotics in animals | journal = Arzneimittel-Forschung | volume = 27 | issue = 8 | pages = 1589â€“95 | year = 1977 | pmid = 410422 | doi = | url = |display-authors=etal}}</ref><ref name="isbn0-412-46630-9">{{cite book | author = David J. Triggle | title = Dictionary of Pharmacological Agents | publisher = Chapman & Hall/CRC | location = Boca Raton | year = 1996 | pages = | isbn = 0-412-46630-9 | oclc = | doi = | url = https://books.google.com/books?id=DeX7jgInYFMC&lpg=PA914&as_brr=3&pg=PA914#v=onepage&q&f=false}}</ref> This profile of effects is similar to that of related agents like [[amoxapine]], [[loxapine]], and [[trimipramine]] which may also be used in the treatment of both [[major depression|depression]] and [[psychosis]].<ref name="isbn0-12-040514-8"/> It was believed that such duality would be advantageous in the treatment of [[schizophrenia]], as depression is often comorbid with the disorder and usual antipsychotics often worsen such symptoms.<ref name="isbn0-12-040514-8"/> In any case, however, fluotracen was never marketed.<ref name="isbn0-412-46630-9"/>
